Cilomilast: Pharmacokinetic and pharmacodynamic interactions with digoxin

Clinical Therapeutics

Volumn 23, Issue 6, 2001, Pages 921-931

  Zussman, Barry D ^a   Kelly, John ^a   Murdoch, Robert D ^a   Clark, David J ^a   Schubert, Christina ^b   Collie, Hazel ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Focus Clinical Drug Development GmbH   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Cilomilast; Digoxin; Interaction; Pharmacokinetics

Indexed keywords

CILOMILAST; DIGOXIN; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; REDUCTION; STEADY STATE; URINALYSIS;

EID: 0034979947     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80079-5     Document Type: Article

References (17)

1. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
2. Risk factors and manifestations of digoxin toxicity in the elderly
3. COPD: Overview of definitions, epidemiology, and factors influencing its development
4. Current issues in the management of chronic obstructive pulmonary diseases
5. Depressant effect of digoxin on atrioventricular conduction in man
6. Clinical pharmacokinetics of digoxin
7. Digoxin toxicity in the aged. Characterising and avoiding the problem
8. Ariflo®, a novel and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for drug-drug interactions
9. The safety and tolerability of Ariflo® (SB 207499), a novel and selective phosphodiesterase inhibitor, in healthy male volunteers
10. Concepts and controversies of bronchodilator overdose
11. Theophylline toxicity
12. Pharmacokinetic interactions with digoxin
13. International Conference on Harmonisation; Guideline on Studies in Support of Special Populations; Geriatrics
14. Sample size determination for bioequivalence assessment by means of confidence intervals
15. A distribution-free procedure for the statistical analysis of bioequivalence studies
16. Pharmacokinetic optimisation of drug therapy in elderly patients
17. Digoxin in the elderly: Pharmacokinetic consequences of old age